Medtronic, a healthcare technology company based in Ireland, plans to separate its diabetes business into a standalone, publicly traded company by the end of 2026.
The company announced the move May 21, noting the new entity will be a direct-to-consumer business and “the only company to commercialize a complete intensive insulin management ecosystem,” according to a news release.
The diabetes unit employs more than 8,000 people worldwide and represented 8% of Medtronic’s fiscal year 2025 revenue.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
